Latest Breaking News On - Open label extension - Page 1 : comparemela.com

PharmAust Drug Shows 91% Increase in MND/ALS Survival

Pharmaust Limited (AU:PAA) has released an update. PharmAust Limited has announced the completion of enrolment for their Open-Label Extension study.

Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema

Donidalorsen delivered significant and sustained reductions in HAE attacks, with high levels of disease control and improvement in quality of life measures with monthly or every two-month dosing;.

Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)

U.S. FDA approves new one pill, once-daily AUSTEDO XR tablets AUSTEDO XR offers more flexibility with the most once-daily doses of any vesicular monoamine transporter 2 inhibitor for effective.

Vera Therapeutics Presents 72-week eGFR Stabilization and

Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress